Aquestive Therapeutics, Inc. AQST Warrants and Rights Outstanding

Warrants and Rights Outstanding at other companies

Zevra Therapeutics, Inc.ZVRA

——

Revenue$14.4M+65.7%

Gross profit$11.0M+117%

Operating income-$4.2M+78.3%

Net income-$8.1M+64.9%

EPS (diluted)-$0.07+70.8%

Cash & equivalents$110.7M+61.3%

Total debt$64.4M+7.4%

Total equity-$34.1M+44.1%

Total assets$141.1M+38.0%

Operating cash flow-$14.8M+36.7%

CapEx$52.0K-61.5%

Free cash flow-$14.9M+36.9%

Market cap$560.13M+73.5%

Enterprise value$513.76M+63.6%

P/S11.1×+5.2×

Gross margin63.5%-4.9pp

Operating margin-111.2%+96.3pp

Net margin-137.1%+80.7pp

FCF margin-88.2%-2.2pp

Return on equity145.1%—

Debt / equity-1.9×—

Current ratio4.1×-0.8×

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Aquestive Therapeutics, Inc.'s warrants and rights outstanding?: Aquestive Therapeutics, Inc. (AQST) reported warrants and rights outstanding of 375K in Q1 2026.